Introduction
With the`greying' of society and the promotion of men's health issues through the pages of the popular press, the increase in the number of men presenting with benign prostatic hyperplasia (BPH) seems set to continue. Fortunately, we have recently seen the emergence of data that have continued to clarify the appropriate role of medical therapies in the management of BPH. However, the clinical data have, for the most part, focused on the impact of medical therapies on what can be considered as the short-term goals of treatment; namely, symptom relief and the alleviation of obstruction, demonstrated as an improvement in maximum urinary¯ow rate (Q max ).
This period has also witnessed an evolution in terms of the very de®nition of the disease. No longer do we talk about`prostatism', a non-speci®c term applied to urinary symptoms in men, but of`true' or`clinical' BPH with resultant bladder out¯ow obstruction. This describes the clinical co-existence of benign prostatic enlargement, outow obstruction and lower urinary tract symptoms ( Figure 1 ). Of particular note, has been the publication of epidemiological data that have re®ned our understanding of the disease's natural history and therefore the long-term goals of its management. Clinical data published earlier this year in the New England Journal of Medicine, presented new opportunities and challenges to the physician in terms of the appropriate use of medical management and the prevention of the long-term complications of the disease, such as acute urinary retention (AUR) and the need for surgery.
Therapeutic options
Management of BPH has traditionally focused on two therapeutic options: watchful waiting and surgery. Transurethral resection of the prostate (TURP) is the treatment of choice for patients with severe obstruction as a result of BPH, and an absolute requirement for those with complications of BPH, for example, AUR, recurrent urinary tract infections, upper tract dilatation, bladder stone formation and recurrent haematuria. Watchful waiting may be selected in cases where there is no absolute indication for surgery. This also depends, however, on how worried the patient is by his symptoms, the impact of which is highly variable.
Medical management represents a third and increasingly important treatment option to watchful waiting and surgery, with the two principal medical therapies being 5a-reductase inhibitors and a 1 -blockers. These drugs are both considered to be appropriate treatment options in patients with bothersome symptoms of BPH who have not developed serious complications of BPH.
1 Both therapies achieve the short-term management objectives for BPH by providing symptom relief and improving Q max , albeit by very different mechanisms.
Finasteride, the only currently approved 5a-reductase inhibitor, inhibits the conversion of testosterone to dihydrotestosterone, the main intracellular androgen which modulates prostatic growth. This results in a 20±30% reduction in prostate size and consequently symptom improvement and reduced obstruction. In contrast, a 1 -blockers reduce the tone of the smooth muscle within the prostate, the bladder neck and the urethra to bring about their bene®cial effects on symptoms and obstruction. However, a 1 -blockers do not affect prostate size and do not halt the natural progression of the disease.
Treatment outcome predictors
The availability of treatment outcome predictors assists the physician in choosing the most appropriate treatment for an individual patient. Potential predictors include age, symptom severity and frequency, bothersomeness of symptoms, peak¯ow rate, prostate size, prostate-speci®c antigen (PSA) level, etc. However, few of these outcome predictors have been systematically analysed as to their potential value in speci®cally tailoring medical treatment.
One factor that has been studied in detail is prostate size. A meta-analysis has been conducted on six randomised clinical trials, which compared treatment with ®nasteride to placebo over a 1 y period. 2 Prostate size, as determined by either transrectal ultrasonography or magnetic resonance imaging, varied at baseline by 50% (37± 60 ml). Strati®cation of patients according to prostate size demonstrated convincingly that the response to treatment with ®nasteride was dependent on baseline prostate volume, that is the larger the prostate, the greater the improvement in peak¯ow rate and symptom score ( Figure 2 ). Overall, the greatest response to ®nasteride treatment was seen in patients with baseline prostate volumes greater than 40 ml.
It is well established that PSA values increase in line with the development of BPH. Indeed, Stamey et al 3 reported that PSA values rise on average by 0.31 ng/ml for every gram of BPH tissue present. It follows, therefore, that the total PSA value may act as a surrogate for the amount of BPH tissue present. This has been con®rmed in a study involving over 4000 men with clinical BPH, in which a log±linear relationship was identi®ed between prostate volume and PSA measurement. 4 This relationship could be important in identifying patients with prostates over certain threshold sizes, in instances where prostate size is an important determinant in selecting a particular therapeutic option. Indeed, data are beginning to emerge that patients with PSA values above 1.3 ng/ml are more likely to respond favourably to 5a-reductase inhibitors such as ®nasteride. 5 In this 4 y placebo controlled study involving 3040 patients with BPH, patients with a baseline PSA value greater than 1.3 ng/ml treated with ®nasteride experienced a signi®cantly (P`0.001) better improvement in symptom score over patients treated with placebo than similarly treated patients with baseline PSA values less than 1.3 ng/ml: 2.8± 3.1 points vs 0.5 points. Given that many patients have their PSA measured as part of the routine work-up, this marker, used in conjunction with the ®ndings on digital rectal examination (DRE), can help the clinician decide which patients should be treated with ®nasteride. Conversely, patients with lower PSA values and small-feeling glands appear more likely to bene®t from a 1 -blockers.
Natural history of BPH
Until recently there has been a relative dearth of available evidence regarding the aetiology of BPH and its associated complications. However, this situation has changed with the publication of the Olmsted County Study of Urinary Symptoms and Health Status Among Men, a community based study involving 2115 men. 6 This study included a random sampling of men aged 40± 79 y, with collection of data over a 42 month period. The severity of symptoms associated with BPH were shown to increase with time and were greatest in older men. Prostate size also increased with age, the overall rate being 0.6 ml/y. Importantly, men with larger prostates ( b 40 ml) were nearly three times as likely to have elevated symptoms, twice as likely to be worried by those symptoms and twice as likely to experience interference with daily living activities than men with smaller prostates.
Disease progression can also be viewed from the perspective of complications and their development. As stated previously, AUR is one of the major complications of BPH. In the Olmsted County Study, the incidence of AUR was found to increase with age; the cumulative incidence at 5 y in men aged 40±49 y was 1.6%, rising to 10% in men aged 70±79 y. The incidence of AUR within any age group was also shown to increase with greater symptom severity. Among men with moderate to mild symptoms, the incidence of AUR was three-fold greater than in men with mild to no symptoms. Importantly, prostate size was identi®ed as a risk factor for developing AUR; for prostate volumes greater than 30 ml, the risk of AUR increased three-fold.
Preventing the complications of BPH
During the last 18 months we have seen the emergence of clinical data that demonstrate that the 5a-reductase inhibitor, ®nasteride, not only improves symptoms and¯ow rate in the short-term, but also reduces the long-term complications associated with BPH. A pooled analysis was conducted on three placebo-controlled, randomised, prospective trials involving 4222 men with BPH treated with ®nasteride (5 mg/d) over 2 y. 7 At baseline, patient characteristics, given as mean (s.d.) values, were: Q max , 11.0 (5.2) ml/s; prostate volume, 40.1 (20.7) ml; and symptom score, 14.5 (7.2). Results showed that patients treated with ®nasteride had a lower incidence of AUR than those in the placebo groups: 1.1% vs 2.7% (P`0.001). With regard to the need for surgery, similar reductions were noted; the rate of surgical intervention in the ®nasteride group was 4.2% compared with 6.5% in the placebo group (P 0.002).
A recently completed study, the Proscar Long-Term Ef®cacy and Safety Study (PLESS) 8 , has now extended these results to 4 y therapy with ®nasteride. A total of 3040 patients with BPH were enrolled at 95 centres in the USA during 1990 and 1992. Patients were diagnosed on the basis of moderate to severe symptoms of urinary obstruction, decreased Q max (`15 ml/s) and an enlarged prostate on DRE. In terms of reducing the need for surgery, 69 (5%) men in the ®nasteride group underwent surgery compared with 152 (10%) men in the placebo group (reduction in risk with ®nasteride 55%; P`0.001) (Table 1, Figure 3 ). In the ®nasteride group, the probability of undergoing TURP was 49% lower than in the placebo group. With regard to the development of AUR, 99 (7%) men in the placebo group compared with 42 (3%) men in the ®nasteride group developed AUR (reduction in risk with ®nasteride 57%; P`0.001). Interestingly, the differences between the two groups were evident and signi®cant in nature within four months and continued throughout the 4 y period. The cost of disease progression AUR is a painful and distressing condition associated with a signi®cant morbidity and requiring hospitalisation, catheterisation and often surgery. The costs associated with treatment of AUR can be substantial. A recent study from the UK reviewing the surgical outcome in 3966 men undergoing prostatectomy found that nearly a third of men (31%) presented in AUR. 9 The authors found that this group were at higher risk of developing complications and death than men who underwent elective prostatectomy. These differences were only partly accounted for by renal impairment, age and co-morbidity.
Although providing the highest likelihood of relief of both prostatic symptoms and urodynamic obstruction, surgical intervention for BPH with procedures such as TURP can have a signi®cant impact on the patient's sexual function. Rates of erectile dysfunction as high as 14.0% have been reported following TURP, 10 as well as retrograde ejaculation rates of 68%.
11 Moreover, evidence suggests that surgery for BPH carried out as an emergency for AUR carries greater morbidity than elective TURP.
12,13

Conclusion
Our understanding of the natural history of BPH and consequently the de®nition has been clari®ed in recent years. Although this disease continues to impose an increasing burden on our society, use of pre-treatment predictors, such as prostate size, to select the most appropriate medical therapy for the individual patient are helping to alleviate this.
The notion of prevention is a relatively new one to the ®eld of urology. If we calculate the numbers needed to treat these preventative outcomes, then 15 men would need to be treated with ®nasteride for 4 y to prevent one event (either surgery or AUR). Whereas prevention is the sole treatment rationale in other therapeutic areas such as hypertension or hyperlipidaemia, these preventative bene®ts should be seen as being additional to ®nasteride's impact upon symptoms and¯ow rates, both in the shortand the long-term. Our challenge in applying these data to clinical practice is to identify those patients who will bene®t most from ®nasteride in terms of symptoms and ow, and who are at most risk of developing long-term complications. This will provide bene®ts in terms of cost-effectiveness. Given recent evidence, an enlarged prostate ( b 40ml) appears to be the pivotal factor in helping to identify such patients. In contrast, those with smaller prostates are at less risk of developing long-term complications and are less likely to bene®t from ®naster-ide. In these patients, a 1 -blockers are probably the medical management of choice.
Clearly, the devastation caused to the patient by a heart attack is, of course, far greater than the development of AUR. Nevertheless, the social and psychological disruption and the risk of complications caused by AUR are not inconsiderable. It is important that clinicians nowadays consider preventative strategies, as well as short-term symptom relief, when selecting a treatment option for patients with BPH.
